<DOC>
	<DOCNO>NCT00717847</DOCNO>
	<brief_summary>We hypothesize Epidermal growth factor receptor tyrosine kinase inhibitor modulate tumor change may reflect alteration serum protein . Study objective : - To establish serum proteomic change patient non-small cell lung cancer ( NSCLC ) receive erlotinib gefitinib . - To identify serum protein profile predict erlotinib gefitinib sensitivity resistance NSCLC patient without EGFR mutation . - To study toxicity erlotinib gefitinib correlate clinical toxicity serum protein profile .</brief_summary>
	<brief_title>A Study Serum Protein Profiling Patients With Non-Small Cell Lung Cancer Treated With Gefitinib Erlotinib</brief_title>
	<detailed_description>Background : Although success achieve identify Epidermal growth factor receptor ( EGFR ) mutation molecular predictive marker response patient non-small cell lung cancer ( NSCLC ) , strategy likely limited respond patient mutation tumor conversely , patient mutation responder . Furthermore , development resistance EGFR tyrosine kinase inhibitor ( TKI ) gefitinib , erlotinib inevitable pose major clinical problem due limit therapeutic option , identification molecular profile could predict sensitivity erlotinib gefitinib warrant . Hypothesis : Using serum easily accessible biological fluid , hypothesize EGFR TKIs modulate tumor change may reflect alteration serum protein . Objectives : - To establish serum proteomic change NSCLC patient receive erlotinib gefitinib . - To identify serum protein profile predict erlotinib gefitinib sensitivity resistance NSCLC patient without EGFR mutation . - To study toxicity erlotinib gefitinib correlate clinical toxicity serum protein profile . Significance : An extensive profiling molecular circuitry affect EGFR TKIs would helpful understanding response side effect patient NSCLC treat erlotinib gefitinib could guide therapy thus improve patient outcome .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Any patient NSCLC receive erlotinib gefitinib . Patients unexpected and/or severe treatment related toxicity whilst receive EGFR TKI . Age â‰¥ 18 year Written inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>